Practical Aspects Of New European Guideline On Quality Assurance & Control Of Pharmaceutical Excipients To Be Discussed By Catalent At IPEC-Europe C...

Somerset, N.J. – February 1, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Daniel Pearce, Quality Director, Global Supplier Assurance, will be presenting at the upcoming International Pharmaceutical Excipients Council (IPEC) Europe Excipients Forum, “Minimizing Risk, Maximizing Quality to Maintain Patient Safety” , to be held at the Negresco Hotel, Nice, France, on February 4th, 2016.

Mr. Pearce has been working on a taskforce set up by IPEC Europe to create a ‘How To’ guide for the practical approaches necessary to comply with a new EU guideline published in March 2015. This guideline requires all manufacturers to conduct a formalized risk assessment to determine the appropriate GMP to apply to excipient manufacture, specific for the dosage form and the risks to patients presented by all products. Mr. Pearce will present the taskforce’s draft document during the one day symposium at 11:00 a.m.

Mr. Pearce joined Catalent in February 2014, and has more than ten years of quality assurance experience in previous roles at Genus Pharmaceuticals and Patheon. He holds a greenbelt in lean six-sigma, and has undertaken all training for EU Responsible and Qualified Person status.

For more information on the 2016 IPEC Europe Excipients Forum, visit: and to arrange a meeting with a Mr. Pearce at the event, contact Richard Kerns at NEPR- .

Media Contacts:  
Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0) 161 728 5880

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™